{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:38:36Z","timestamp":1793504316768,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA014520, P50 DE026787, 1DP5OD024576, U01CA233102"],"award-info":[{"award-number":["P30 CA014520, P50 DE026787, 1DP5OD024576, U01CA233102"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.591139","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T08:19:37Z","timestamp":1605169177000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Won Jong","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Erbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara N.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail A.","family":"Jaquish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce R.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghava N.","family":"Sriramaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Jagodinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber M.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Hsueh","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.824","article-title":"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival","volume":"90","author":"Rubin Grandis","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2823","article-title":"Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study","volume":"23","author":"Hirsch","year":"2005","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.113","article-title":"Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck","volume":"59","author":"Ishitoya","year":"1989","journal-title":"Br J Cancer"},{"key":"B4","article-title":"Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer","volume":"53","author":"Grandis","year":"1993","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S93720","article-title":"Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors","volume":"9","author":"Sacco","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1517\/13543781003769844","article-title":"Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma","volume":"19","author":"Cassell","year":"2010","journal-title":"Expert Opin Invest Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-008-0027-6","article-title":"The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck","volume":"6","author":"Mehra","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"B10","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2318","article-title":"New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors","volume":"16","author":"Chen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.19","article-title":"Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members","volume":"27","author":"Wheeler","year":"2008","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.06.023","article-title":"Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells","volume":"108","author":"Saki","year":"2013","journal-title":"Radiother Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2017.05.006","article-title":"Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies","volume":"58","author":"Park","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2644","article-title":"In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments","volume":"76","author":"Morris","year":"2016","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0223","article-title":"Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade","volume":"5","author":"Haymaker","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0238","article-title":"Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases","volume":"4","author":"Alomari","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.05.001","article-title":"Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition","volume":"3","author":"von Reibnitz","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.6009","article-title":"A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)","volume":"36","author":"McBride","year":"2018","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/0471142727.mb2804s106","article-title":"Detection of Mycoplasma contamination in cell cultures","volume":"106","author":"Uphoff","year":"2014","journal-title":"Curr Protoc Mol Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200405000-00005","article-title":"Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer","volume":"27","author":"Connor","year":"2004","journal-title":"J Immunother"},{"key":"B35","doi-asserted-by":"publisher","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0155","article-title":"Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers","volume":"14","author":"Li","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1831","article-title":"ERK1\/2 regulation of CD44 modulates oral cancer aggressiveness","volume":"72","author":"Judd","year":"2012","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/0194599812442037","article-title":"Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer","volume":"147","author":"Judd","year":"2012","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"Ercan","year":"2012","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-3-15","article-title":"Phospholipase C delta-4 overexpression upregulates ErbB1\/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells","volume":"3","author":"Leung","year":"2004","journal-title":"Mol Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.127.4.1585","article-title":"Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes","volume":"127","author":"Hokland","year":"1981","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0008-8749(91)90255-a","article-title":"Activation of macrophages for ADCC in vitro: effects of IL-4, TNF, interferons-alpha\/beta, interferon-gamma, and GM-CSF","volume":"135","author":"Fan","year":"1991","journal-title":"Cell Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.5.2391","article-title":"Interferon gamma production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking","volume":"183","author":"Arase","year":"1996","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.272","article-title":"NKG2D ligands in tumor immunity","volume":"27","author":"Nausch","year":"2008","journal-title":"Oncogene"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D Receptor and Its Ligands in Host Defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3892\/ijo_00000838","article-title":"Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance","volume":"38","author":"Rebucci","year":"2011","journal-title":"Int J Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0153","article-title":"Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma","volume":"17","author":"Leblanc","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B54","first-page":"16","article-title":"Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers","volume":"8","author":"Uppaluri","year":"2008","journal-title":"Cancer Immun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.8724","article-title":"Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma","volume":"28","author":"Thurlow","year":"2010","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2880110408","article-title":"Johnson JT. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer","volume":"11","author":"Snyderman","year":"1989","journal-title":"Head Neck"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s13046-019-1403-9","article-title":"IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression","volume":"38","author":"Thiem","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00610","article-title":"Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells","volume":"7","author":"Derer","year":"2016","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(03)00511-x","article-title":"The epidermal growth factor receptor mediates radioresistance","volume":"57","author":"Liang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90269-0","article-title":"The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities","volume":"29","author":"Bonner","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B63","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis","volume":"6","author":"Huang","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B64","article-title":"In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody","volume":"6","author":"Milas","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.6010","article-title":"Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504","volume":"36","author":"Ferris","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.591139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T04:33:13Z","timestamp":1697085193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.591139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2020.591139"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.591139","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"article-number":"591139"}}